Treatment escape reduces the effectiveness of cabergoline during long ‐term treatment of acromegaly in monotherapy or in association with first‐generation somatostatin receptor ligands

ConclusionWe presented the results of the largest single‐center study with CAB in monotherapy and in combination with SRL. The efficacy of CAB in acromegaly seems to be lower than that of other drugs, and treatment escape may occur after a long‐term follow‐up.This article is protected by copyright. All rights reserved.

Source: Clinical Endocrinology - March 9, 2018 Category: Endocrinology Authors: Leandro Kasuki, Marilia Duarte Dalmolin, Luiz Eduardo Armondi Wildemberg, M ônica R. Gadelha Tags: 4 Original Article ‐ Americas Source Type: research